Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) and Atrinsic (NASDAQ:PTIX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Profitability
This table compares Nautilus Biotechnology and Atrinsic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nautilus Biotechnology | N/A | -35.04% | -29.16% |
| Atrinsic | N/A | N/A | -379.72% |
Analyst Ratings
This is a summary of current recommendations for Nautilus Biotechnology and Atrinsic, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nautilus Biotechnology | 1 | 0 | 1 | 0 | 2.00 |
| Atrinsic | 1 | 0 | 0 | 0 | 1.00 |
Institutional & Insider Ownership
50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 8.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Nautilus Biotechnology and Atrinsic”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nautilus Biotechnology | N/A | N/A | -$59.00 million | ($0.46) | -5.46 |
| Atrinsic | N/A | N/A | -$5.53 million | ($3.45) | -0.19 |
Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Nautilus Biotechnology has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Atrinsic has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Summary
Nautilus Biotechnology beats Atrinsic on 7 of the 11 factors compared between the two stocks.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
About Atrinsic
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
